Timing and Protocols of Clinical and Endoscopic Surveillance of Barrett’s Esophagus

  • Carlo CalabreseEmail author
  • Marco Salice
  • Nico Pagano
  • Raffaele Manta
  • Fernando Rizzello


There has been a rapid increase in the incidence of esophageal adenocarcinoma in most Western countries over the past 30 years. Barrett’s esophagus (BE) is a common premalignant lesion of esophageal adenocarcinoma although the risk of developing cancer in BE remains low. Therefore, screening is not recommended in the general population. Surveillance of BE is recommended to detect high-grade dysplasia or carcinoma in an earlystage although there is no clear evidence that surveillance leads to a reduced mortality. This chapter discusses the time and protocols of clinical and endoscopic surveillance.


Barrett’s esophagus Surveillance Endoscopy Dysplasia Esophageal adenocarcinoma 


  1. 1.
    Fitzgerald RC, di Pietro M, Ragunath K, Ang Y, Kang JY, Watson P, et al. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett’s oesophagus. Gut. 2014;63:7–42.CrossRefPubMedCentralGoogle Scholar
  2. 2.
    Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ, American Gastroenterological A. American Gastroenterological Association technical review on the management of Barrett’s esophagus. Gastroenterology. 2011;140:18–52.CrossRefGoogle Scholar
  3. 3.
    Bennett C, Vakil N, Bergman J, Harrison R, Odze R, Vieth M, et al. Consensus statements for management of Barrett’s dysplasia and early-stage esophageal adenocarcinoma, based on a Delphi process. Gastroenterology. 2012;143:336–46.CrossRefPubMedCentralGoogle Scholar
  4. 4.
    Das D, Chilton AP, Jankowski JA. Chemoprevention of oesophageal cancer and the AspECT trial. Recent Results Cancer Res. 2009;181:161–9.CrossRefPubMedCentralGoogle Scholar
  5. 5.
    Jankowski J, Barr H, Wang K, Delaney B. Diagnosis and management of Barrett’s oesophagus. BMJ. 2010;341:c4551.CrossRefPubMedCentralGoogle Scholar
  6. 6.
    Jankowski J, Barr H. Improving surveillance for Barrett’s oesophagus: AspECT and BOSS trials provide an evidence base. BMJ. 2006;332(7556):1512.CrossRefPubMedCentralGoogle Scholar
  7. 7.
    Ronkainen J, Aro P, Storskrubb T, Johansson SE, Lind T, Bolling-Sternevald E, et al. Prevalence of Barrett’s esophagus in the general population: an endoscopic study. Gastroenterology. 2005;129:1825–31.CrossRefGoogle Scholar
  8. 8.
    Ford AC, Forman D, Reynolds PD, Cooper BT, Moayyedi P. Ethnicity, gender, and socioeconomic status as risk factors for esophagitis and Barrett’s esophagus. Am J Epidemiol. 2005;162:454–60.CrossRefGoogle Scholar
  9. 9.
    Malfertheiner P, Lind T, Willich S, Vieth M, Jaspersen D, Labenz J, et al. Prognostic influence of Barrett’s oesophagus and Helicobacter pylori infection on healing of erosive gastro-oesophageal reflux disease (GORD) and symptom resolution in non-erosive GORD: report from the ProGORD study. Gut. 2005;54:746–51.CrossRefPubMedCentralGoogle Scholar
  10. 10.
    Coleman HG, Bhat S, Murray LJ, McManus D, Gavin AT, Johnston BT. Increasing incidence of Barrett’s oesophagus: a population-based study. Eur J Epidemiol. 2011;26:739–45.CrossRefPubMedCentralGoogle Scholar
  11. 11.
    Taylor JB, Rubenstein JH. Meta-analyses of the effect of symptoms of gastroesophageal reflux on the risk of Barrett’s esophagus. Am J Gastroenterol. 2010;105:1729–37.CrossRefPubMedCentralGoogle Scholar
  12. 12.
    Ronkainen J, Talley NJ, Storskrubb T, Johansson SE, Lind T, Vieth M, et al. Erosive esophagitis is a risk factor for Barrett’s esophagus: a community-based endoscopic follow-up study. Am J Gastroenterol. 2011;106:1946–52.CrossRefPubMedCentralGoogle Scholar
  13. 13.
    Erichsen R, Robertson D, Farkas DK, Pedersen L, Pohl H, Baron JA, et al. Erosive reflux disease increases risk for esophageal adenocarcinoma, compared with nonerosive reflux. Clin Gastroenterol Hepatol. 2012;10:475–80.CrossRefPubMedCentralGoogle Scholar
  14. 14.
    Malfertheiner P, Nocon M, Vieth M, Stolte M, Jaspersen D, Koelz HR, et al. Evolution of gastro-oesophageal reflux disease over 5 years under routine medical care--the ProGERD study. Aliment Pharmacol Ther. 2012;35:154–64.CrossRefPubMedCentralGoogle Scholar
  15. 15.
    Lagergren J, Lagergren P. Recent developments in esophageal adenocarcinoma. CA Cancer J Clin. 2013;63:232–48.CrossRefPubMedCentralGoogle Scholar
  16. 16.
    Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.CrossRefPubMedCentralGoogle Scholar
  17. 17.
    Solaymani-Dodaran M, Card TR, West J. Cause-specific mortality of people with Barrett’s esophagus compared with the general population: a population-based cohort study. Gastroenterology. 2013;144:1375–83.CrossRefPubMedCentralGoogle Scholar
  18. 18.
    Anderson LA, Murray LJ, Murphy SJ, et al. Mortality in Barrett’s oesophagus: results from a population based study. Gut. 2003;52:1081–4.CrossRefPubMedCentralGoogle Scholar
  19. 19.
    Bennett C, Moayyedi P, Corley DA, Den Caestecker J, Falck-Ytter Y, Falk G, et al. BOB CAT: a large-scale review and Delphi consensus for management of Barrett’s esophagus with No Dysplasia, indefinite for, or low-grade Dysplasia. Am J Gastroenterol. 2015;110:662–82.CrossRefPubMedCentralGoogle Scholar
  20. 20.
    Evans J, Early D, Fukami N, Ben-Menachem T, Chandrasekhara V, Chathadi K, et al. The role of endoscopy in Barrett’s esophagus and other premalignant conditions of the esophagus. Gastrointest Endosc. 2012;76:1087–94.CrossRefPubMedCentralGoogle Scholar
  21. 21.
    Shaheen NJ, Falk GW, Iyer PG, Gerson L. ACG clinical guideline: diagnosis and management of Barrett’s esophagus. Am J Gastroenterol. 2015;111:30–50.CrossRefPubMedCentralGoogle Scholar
  22. 22.
    American Gastroenterological Association, Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ. American gastroenterological association medical position statement on the management of Barrett’s esophagus. Gastroenterology. 2011;140:1084–91.CrossRefGoogle Scholar
  23. 23.
    Sikkema M, Looman CW, Steyerberg EW, Kerkhof M, Kastelein F, van Dekken H, et al. Predictors for neoplastic progression in patients with Barrett’s Esophagus: a prospective cohort study. Am J Gastroenterol. 2011;106:1231–8.CrossRefPubMedCentralGoogle Scholar
  24. 24.
    Phoa KN, van Vilsteren FG, Weusten BL, Bisschops R, Schoon EJ, Ragunath K, et al. Radiofrequency ablation vs endoscopic surveillance for patients with Barrett esophagus and low-grade dysplasia: a randomized clinical trial. JAMA. 2014;311:1209–17.CrossRefPubMedCentralGoogle Scholar
  25. 25.
    Bhat S, Coleman HG, Yousef F, et al. Risk of malignant progression in Barrett’s esophagus patients: results from a large population-based study. J Natl Cancer Inst. 2011;103:1049–57.CrossRefPubMedCentralGoogle Scholar
  26. 26.
    Nunobe S, Nakanishi Y, Taniguchi H, et al. Two distinct pathways of tumorigenesis of adenocarcinomas of the esophagogastric junction, related or unrelated to intestinal metaplasia. Pathol Int. 2007;57:315–21.CrossRefPubMedCentralGoogle Scholar
  27. 27.
    Hvid-Jensen F, Pedersen L, Drewes AM, et al. Incidence of adenocarcinoma among patients with Barrett’s esophagus. N Engl J Med. 2011;365:1375–83.CrossRefGoogle Scholar
  28. 28.
    Bisschops R. Optimal endoluminal treatment of Barrett’s esophagus: integrating novel strategies into clinical practice. Expert Rev Gastroenterol Hepatol. 2010;4:319–33.CrossRefGoogle Scholar
  29. 29.
    Fountoulakis A, Zafirellis KD, Dolan K, Dexter SPL, Martin IG, Sue-Ling HM. Effect of surveillance of Barrett’s oesophagus on the clinical outcome of oesophageal cancer. Br J Surg. 2004;91:997–1003.CrossRefGoogle Scholar
  30. 30.
    Lerut T, Coosemans W, Van Raemdonck D, Dillemans B, De Leyn P, Marnette JM, et al. Surgical treatment of Barrett’s carcinoma. Correlations between morphologic findings and prognosis. J Thorac Cardiovasc Surg. 1994;107:1059–65.PubMedGoogle Scholar
  31. 31.
    Sharma P, Falk GW, Weston AP, Reker D, Johnston M, Sampliner RE, et al. Dysplasia and Cancer in a large multicenter cohort of patients with Barrett’s Esophagus. Clin Gastroenterol Hepatol. 2006;4:566–72.CrossRefPubMedCentralGoogle Scholar
  32. 32.
    Sharma P. Barrett’s esophagus. N Engl J Med. 2009;26361:2548–56.CrossRefGoogle Scholar
  33. 33.
    Kastelein F, van Olphen S, Steyerberg EW, Sikkema M, Spaander MCW, Looman CWN, et al. Surveillance in patients with long-segment Barrett’s oesophagus: a cost-effectiveness analysis. Gut. 2015;64:864–71.CrossRefPubMedCentralGoogle Scholar
  34. 34.
    Rubenstein JH, Scheiman JM, Sadeghi S, Whiteman D, Inadomi JM. Esophageal adenocarcinoma incidence in individuals with gastroesophageal reflux: synthesis and estimates from population studies. Am J Gastroenterol. 2011;106:254–60.CrossRefPubMedCentralGoogle Scholar
  35. 35.
    Provenzale D, Schmitt C, Wong JB. Barrett’s esophagus: a new look at surveillance based on emerging estimates of cancer risk. Am J Gastroenterol. 1999;94:2043–53.CrossRefPubMedCentralGoogle Scholar
  36. 36.
    Corley DA, Levin TR, Habel LA, Weiss NS, Buffler PA, McKinney A, et al. Surveillance and survival in Barrett’s adenocarcinomas: a population-based study. Gastroenterology. 2002;122:633–40.CrossRefPubMedCentralGoogle Scholar
  37. 37.
    Hu Q, Sun T-T, Hong J, Fang J-Y, Xiong H, Meltzer SJ. Proton pump inhibitors do not reduce the risk of esophageal adenocarcinoma in patients with Barrett’s esophagus: a systematic review and meta-analysis. PLoS One. 2017;12:e0169691.CrossRefPubMedCentralGoogle Scholar
  38. 38.
    Singh S, Garg SK, Singh PP, Iyer PG, El-Serag HB. Acid-suppressive medications and risk of oesophageal adenocarcinoma in patients with Barrett’s oesophagus: a systematic review and meta-analysis. Gut. 2014;63:1229–37.CrossRefPubMedCentralGoogle Scholar
  39. 39.
    Levine DS, Blount PL, Rudolph RE, et al. Safety of a systematic endoscopic biopsy protocol in patients with Barrett’s esophagus. Am J Gastroenterol. 2000;95:1152–7.CrossRefPubMedCentralGoogle Scholar
  40. 40.
    Ross-Innes CS, Debiram-Beecham I, O’Donovan M, Walker E, Varghese S, Lao-Sirieix P, et al. Evaluation of a minimally invasive cell sampling device coupled with assessment of trefoil factor 3 expression for diagnosing Barrett’s esophagus: a multi-center case-control study. PLoS Med. 2015;12:1–19.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2019

Authors and Affiliations

  • Carlo Calabrese
    • 1
    Email author
  • Marco Salice
    • 1
  • Nico Pagano
    • 2
  • Raffaele Manta
    • 3
  • Fernando Rizzello
    • 1
  1. 1.Department of Medicine and SurgeryUniversity Alma Mater Bologna, Italy—School of MedicineBolognaItaly
  2. 2.Gastroenterology and Digestive Endoscopy Unit, Department of Medical and Surgical Sciences (DIMEC)University Alma Mater Bologna, Italy—School of MedicineBolognaItaly
  3. 3.Gastroenterology and Digestive Endoscopy UnitNOCSAE Hospital of ModenaModenaItaly

Personalised recommendations